Immunologic desensitization to nilotinib in a patient with chronic myeloid leukemia with hypersensitivity and complex comorbidities.
OpenAlex 토픽 ·
Chronic Myeloid Leukemia Treatments
Drug-Induced Adverse Reactions
Myeloproliferative Neoplasms: Diagnosis and Treatment
Desensitization to nilotinib offers a viable solution for patients with chronic myeloid leukemia who are experiencing hypersensitivity, thus enabling continuation of targeted therapy.
APA
Triaji Suryo Condro Widagdo, Deasy Fetarayani, et al. (2026). Immunologic desensitization to nilotinib in a patient with chronic myeloid leukemia with hypersensitivity and complex comorbidities.. The journal of allergy and clinical immunology. Global, 5(3), 100679. https://doi.org/10.1016/j.jacig.2026.100679
MLA
Triaji Suryo Condro Widagdo, et al.. "Immunologic desensitization to nilotinib in a patient with chronic myeloid leukemia with hypersensitivity and complex comorbidities.." The journal of allergy and clinical immunology. Global, vol. 5, no. 3, 2026, pp. 100679.
PMID
42006153
Abstract
Desensitization to nilotinib offers a viable solution for patients with chronic myeloid leukemia who are experiencing hypersensitivity, thus enabling continuation of targeted therapy. This approach supports molecular remission even in the presence of complex metabolic and neurologic comorbidities.